Pharmacogenomic testing is designed to detect clinically important genetic variants that influence drug metabolism. These variants change the rate at which certain drugs are activated and broken down. This information can help doctors predict whether a medication is likely to be effective or cause serious side-effects.
An important gap in the evidence supporting the use of pharmacogenomics(PGx) tests in Australia, is the lack of information about the frequencies of genetic variants among Aboriginal and Torres Strait Islander peoples.
The Australian Pharmacogenomics Diversity Project (MDD-PGx) seeks to re-genotype and analyse samples collected in a nation-wide study of depression (The Australian Genetics of Depression Study; AGDS).
The aim of the AGDS study was to recruit adult Australians with lived experience of Major Depression Disorder (MDD) and investigate specific genetic risk factors associated with differences between individuals in terms of both: risk of depression and response to treatment. Since the study began in 2015, over 20,000 individuals have participated in the AGDS study.
At CQUniversity we are committed to embedding sustainable practice in our operations, interactions and relationships, underpinned by the United Nations Sustainable Development Goals. Sustainability is one of our strategic pillars within our Strategic Plan 2019-2023.
This project aligns with the following SDG Goals:
CQUniversity acknowledges Traditional Owners and Custodians and pays respect to the Elders of all First Nations peoples of Australia.CQUniversity Australia is a trading name of Central Queensland University
ABN: 39 181 103 288
RTO Code: 40939
CRICOS: 00219C
TEQSA: PRV12073
